Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of a Digital Mindfulness Intervention on Mental Health and Vision-Related Quality of Life in Non-infectious Uveitis.

Ophthalmology·2026
Same author

Rethinking the Link between Ophthalmic Herpes and Malignancy.

Ophthalmology·2026
Same author

Integrated metagenomic sequencing and phage display-based immunoprecipitation sequencing for presumptive viral infection: a case report.

American journal of ophthalmology case reports·2026
Same author

OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Ophthalmology science·2026
Same author

Risk Factors for Long COVID Among Individuals with Noninfectious Uveitis in a Large United States Claims Database.

Ocular immunology and inflammation·2026
Same author

Novel advances in juvenile idiopathic arthritis associated uveitis.

Arthritis research & therapy·2026
Same journal

Ocular toxoplasmosis in Latin American and European patients: clinical characteristics, visual outcomes, and recurrence patterns.

Journal of ophthalmic inflammation and infection·2026
Same journal

Severe corneal melting with necrotic sloughing in Acanthamoeba keratitis mimicking corneal endotheliitis.

Journal of ophthalmic inflammation and infection·2026
Same journal

Delayed-onset cytomegalovirus retinitis after 0.2 µg/day fluocinolone acetonide implantation: a case series.

Journal of ophthalmic inflammation and infection·2026
Same journal

Evaluation of corneal intrastromal voriconazole injection as an adjuvant approach in recalcitrant fungal keratitis.

Journal of ophthalmic inflammation and infection·2026
Same journal

Occlusive retinal vasculopathy on ultrawide-field fluorescein angiography in intraocular cytomegalovirus infection: a case series.

Journal of ophthalmic inflammation and infection·2026
Same journal

Nocardia brasiliensis endophthalmitis initially misdiagnosed as uveitis: a case report.

Journal of ophthalmic inflammation and infection·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Corticosteroid-sparing therapy: practice patterns among uveitis specialists.

Elizabeth Esterberg1, Nisha R Acharya

  • 1F.I. Proctor Foundation, University of California San Francisco, Room S309, 513 Parnassus Avenue, San Francisco, CA, 94143-0412, USA.

Journal of Ophthalmic Inflammation and Infection
|November 8, 2011
PubMed
Summary
This summary is machine-generated.

Methotrexate remains the top choice for initial corticosteroid-sparing treatment in chronic noninfectious uveitis, despite the perceived effectiveness of newer biologic drugs among experienced specialists.

More Related Videos

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Related Experiment Videos

Last Updated: May 27, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Chronic noninfectious uveitis requires long-term management, often involving corticosteroid-sparing therapies.
  • Understanding current treatment patterns is crucial for optimizing patient care.

Purpose of the Study:

  • To investigate the practice patterns, preferences, and perceptions of uveitis specialists regarding initial corticosteroid-sparing treatments.
  • To identify the most commonly used and preferred immunomodulatory therapies.

Main Methods:

  • A survey was distributed to experienced uveitis specialists via email listservs.
  • Respondents reported on the effectiveness, usage, and preferences for seven immunomodulatory treatments.

Main Results:

  • Methotrexate was the most frequently used initial therapy across all uveitis types (anterior, intermediate, posterior/panuveitis).
  • Mycophenolate mofetil was the most preferred for intermediate and posterior/panuveitis.
  • Barriers to using other treatments included effectiveness, safety, tolerability, cost, and administration difficulty.

Conclusions:

  • Methotrexate is the predominant initial treatment for chronic noninfectious uveitis among experienced specialists.
  • Newer biologic drugs, while considered effective, are not widely adopted as first-line therapy.